Jiho Jang

Dr. Jiho Jang


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2008 in Pacific Focus
Verified
Journal Article
Closed access
PDF file
SKSunhyuk Kim
Sunhyuk Kim
CHChonghee Han
Chonghee Han
JJJiho Jang
Jiho Jang

18 June 2024 in MethodsX
Verified
Journal Article
Open access
AKA-Hyeon Kim
A-Hyeon Kim
HLHa Myoung Lee
Ha Myoung Lee
HKHong-Sik Kim
Hong-Sik Kim
SJSeong Woo Jeong
Seong Woo Jeong
JJJong Kwan Jun
Jong Kwan Jun
JJJiho Jang
Jiho Jang
The method presented herein is associated with the Lab Resource article titled “Generation of αMHC-EGFP knock-in in human pluripotent stem cell line, SNUe003-A-3, using CRISPR/CAS9-based gene targeting” [1]. The cardiac muscle-specific protein, α-myosin heavy chain (αMHC), is encoded by the human MYH6 gene, which is expressed in both the atria and ventricles during embryonic development and is predominantly expressed in the atria after birth [2]. Herein, the methods used to achieve CRISPR/SpCas9-mediated introduction of an EGFP reporter into αMHC, the target locus in human pluripotent stem cells (hPSCs) for cardiac lineage tracing and clinical cell sorting are described. The CRISPR-Cas9 system enables efficient replacement of the stop codon in the last exon of αMHC with a 2A non-joining peptide (T2A)-EGFP cassette. First, hPSCs are transfected with the donor construct and Cas9/sgRNA plasmids via electroporation and selected with neomycin for approximately 3 weeks. Thereafter, the established cell line exhibits typical characteristics of human embryonic stem cells (hESCs). When these cells differentiate into cardiomyocytes, the expression of EGFP is confirmed using confocal microscopy, flow cytometry analysis, and immunostaining. • The line enables monitoring of cell maturation events during human cardiac development. • The line is a valuable platform for cardiotoxicity tests and drug screening. • This method has already been employed in two original studies, as previously reported for reporter cell line generation using CRISPR/Cas9.

1 May 2021 in Stem Cell Research
Verified
Journal Article
Open access
JJJuwon Jung
Juwon Jung
SHSunsook Hwang
Sunsook Hwang
HSHyewon Seol
Hyewon Seol
AKA-Hyeon Kim
A-Hyeon Kim
HLHa Myoung Lee
Ha Myoung Lee
JJJiho Jang
Jiho Jang
Brachyury is an embryonic nuclear transcription factor required for mesoderm formation and differentiation. Here, we introduced an mCherry reporter into the C-terminus of Brachyury in the human pluripotent stem cell line SNUhES3 using the CRISPR/Cas9 nuclease approach. Successful gene editing was verified by DNA sequencing. SNUhES3-Brachyury-mCherry cells expressed pluripotent stem cell markers, exhibited a normal karyotype, and could generate all three germ layers. This cell line expressed the red fluorescence protein mCherry upon the induction of mesoderm differentiation. This reporter cell line could be used to monitor mesodermal population enrichment during mesodermal differentiation.

4 April 2022 in Stem Cell Research
Verified
Journal Article
Open access
HLHa Myoung Lee
Ha Myoung Lee
AKA-Hyeon Kim
A-Hyeon Kim
SHSunsook Hwang
Sunsook Hwang
JJJuwon Jung
Juwon Jung
HSHyewon Seol
Hyewon Seol
JJJiho Jang
Jiho Jang
The cardiac muscle-specific protein, α-myosin heavy chain (αMHC), is a major component of cardiac muscle filaments involved in cardiac muscle contraction. Here, we established an αMHC-enhanced fluorescent protein (EGFP) knock-in human pluripotent stem cell (hPSC) line by linking the EGFP gene to the C-terminal region of αMHC via a 2A non-joining peptide using CRISPR/Cas9 nuclease. The EGFP reporter precisely reflected the endogenous level of αMHC upon the induction of cardiac differentiation. This reporter cell line will be a valuable platform for cardiotoxicity tests, drug screening, and investigating the pathological mechanisms of cardiomyocytes.

8 March 2023 in Stem Cell Research
Verified
Journal Article
Open access
AKA-Hyeon Kim
A-Hyeon Kim
HLHa Myoung Lee
Ha Myoung Lee
HKHong-Sik Kim
Hong-Sik Kim
JJJuwon Jung
Juwon Jung
HSHyewon Seol
Hyewon Seol
JJJiho Jang
Jiho Jang
TUBB3 is a structural neuronal protein important for multiple neuronal functions including axonal guidance and maturation. This study aimed to generate a human pluripotent stem cell (hPSC) line with a TUBB3-mCherry reporter using CRISPR/SpCas9 nuclease. The stop codon in the last exon of TUBB3 was replaced with a T2A-mCherry cassette using CRISPR/SpCas9-mediated homologous recombination. The established TUBB3-mCherry knock-in cell line exhibited typical pluripotent characteristics. The mCherry reporter faithfully replicated the endogenous level of TUBB3 upon induction of neuronal differentiation. The reporter cell line could contribute to the investigation of neuronal differentiation, neuronal toxicity, and neuronal tracing.

13 August 2026 in Cells
Verified
Journal Article
Open access
PDF file
EKEun Hee Kim
Eun Hee Kim
OBOh Young Bang
Oh Young Bang
GOGyun sik Oh
Gyun sik Oh
MOMi Jeong Oh
Mi Jeong Oh
WLWooJoo Lee
WooJoo Lee
JJJiho Jang
Jiho Jang
Moyamoya disease (MMD) is a progressive cerebrovascular disorder characterized by intracranial arterial stenosis and abnormal collateral vessel formation. The molecular mechanisms by which extracellular vesicle (EV)-derived microRNAs contribute to endothelial dysfunction remain poorly understood. We investigated whether circulating extracellular vesicle-derived microRNAs (EV-miRNAs) contribute to endothelial dysfunction and serve as functional mediators of MMD pathogenesis. Plasma EV-miRNA profiles were compared among patients with MMD, intracranial atherosclerosis (ICAS), and healthy controls, and differentially expressed EV-miRNAs were validated in an independent cohort. Functional studies were performed in human umbilical vein endothelial cells and patient-derived induced pluripotent stem cell-derived endothelial cells. Three EV-miRNAs were significantly upregulated in MMD, among which miR-558 showed the strongest diagnostic performance. miR-558 overexpression impaired endothelial tube formation and proliferation, whereas its inhibition enhanced angiogenic activity. Mechanistically, HMGB2 was identified as a direct target of miR-558, and miR-558 overexpression reduced HMGB2 protein expression. Patient-derived endothelial cells recapitulated increased miR-558 expression, reduced HMGB2 levels, and impaired angiogenic capacity. These findings identify circulating EV-miR-558 a potential biomarker and show that miR-558 suppresses HMGB2 and impairs endothelial angiogenesis in adult MMD, suggesting that the EV-miR-558/HMGB2 pathway represents a potential mechanism underlying endothelial dysfunction and therapeutic target for MMD.